Peruvoside
Jump to navigation
Jump to search
| Clinical data | |
|---|---|
| Other names | (3S,5R,10R,13R,14S,17R)- 3-[(2S,5R)- 3,5-dihydroxy- 4-methoxy- 6-methyloxan- 2-yl]oxy- 14-hydroxy- 13-methyl- 17-(5-oxo-2H-furan-3-yl)- 1,2,3,4,5,6,7,8,9,11,12,15,16,17- tetradecahydrocyclopenta[a]phenanthrene- 10-carbaldehyde |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C30H44O9 |
| Molar mass | 548.673 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
This article may be too technical for most readers to understand. (February 2021) |
Peruvoside (or cannogenin thevetoside) is a cardiac glycoside[1] for heart failure.[2]
It is derived from Cascabela thevetia (Thevetia neriifolia).[2]